使用寡合胆酸的仿制GLP-1A的设计,以利用载体介导内细胞形成,用于口服输送

Seho Kweon1,2, Jun-Hyuck Lee3, Seong-Bin Yang3

  • 1Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea.

Biomaterials research
|September 2, 2023
PubMed
概括

研究人员通过将其与脱氧醇酸 (DOCA) 寡合体结合,开发出一种新的仿制葡萄糖类-1激动剂 (GLP-1A). 这种增强的GLP-1A表现出改善的口服生物可用性和强大的低血糖作用,为糖尿病治疗提供了一个有前途的新策略.

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
519
Receptor-mediated Endocytosis01:39

Receptor-mediated Endocytosis

Overview
104.7K